Brookfield Corp’s Keros Therapeutics KROS Stock Holding History

Brookfield Corp’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,014	Closed	-$433K	–	724
2022 Q4	$433K	Buy	+9,014	New	+$421K	﹤0.01%	544

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Brookfield Corp's KROS Position: Q1 2023 in Review

Brookfield Corp sold out of Keros Therapeutics (KROS) in Q1 2023, closing a stake of 9,014 shares — an estimated $433K sold.

Brookfield Corp first reported a position in KROS in Q4 2022 and held it in 1 quarter. The position peaked at $433K in Q4 2022. 129 funds tracked by Wall St. Rank hold KROS as of Q1 2023.

Brookfield Corp reported no remaining Keros Therapeutics position as of Q1 2023 after selling out during the quarter.
Brookfield Corp sold 9,014 Keros Therapeutics shares in Q1 2023, an estimated $433K.
Brookfield Corp first reported a position in Keros Therapeutics in Q4 2022 and held it in 1 quarter.
Brookfield Corp's Keros Therapeutics position peaked at $433K in Q4 2022.
129 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2023.

Based on Brookfield Corp's 13F filing for Q1 2023, filed 15 May 2023.